“As expected, our financial performance in 2013 reflected the ongoing impact of the loss of exclusivity for several key brands, with revenue down 6% to $25,711 million.”Read the statement
“I am pleased with the momentum we built in 2013 against our strategic priorities, particularly our objective of achieving scientific leadership.”Read the review
At a glance
*All figures are approximate.
Financial summaryOur financial summary
- Restated for new Core definition.
- Restated for new Core definition and adoption of IAS 19 (2011).
- Restated on adoption of IAS 19 (2011).
Life-cycle of a medicine
AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from research, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives.Find out more
How we add value
Our Business model demonstrates how we apply our resources to our chosen therapy areas across the whole life-cycle of a medicine to help deliver our strategic priorities and add value.Find out more